For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and Tafamidis meglumine represents a true breakthrough . These innovative therapies stabilize the transthyretin protein, preventing its harmful build-up and lessening the severity of the disease . People are now seeing improvements in